Alitretinoin Anticancer Drugs Oncology Pharmacology Physiotherapy

Alitretinoin (Clinical Studies-3)

In this article we will discuss Alitretinoin (Clinical Studies-3)

In this article, we will discuss Alitretinoin (Clinical Studies-3). So, let’s get started.

A global evaluation by physicians was also carried out. It considered all of the patient’s treated lesions (index and other) compared to baseline. In this evaluation, patients with at least a 50% improvement in the KS lesions were considered responders. In addition, photographs of lesions in patients considered responders by the modified ACTG criteria were examined by the FDA for a cosmetically
beneficial response, defined as at least a 50% improvement in appearance compared to baseline, considering both the KS lesions and dermal toxicity at the lesion site, in at least 50% of the index lesions and maintained for at least 3 weeks. Patients were also asked about their satisfaction with the treatment.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.